Annual CFF
$8.81 M
-$41.98 M-82.65%
31 December 2022
Summary:
Eloxx Pharmaceuticals annual cash flow from financing activities is currently $8.81 million, with the most recent change of -$41.98 million (-82.65%) on 31 December 2022. During the last 3 years, it has risen by +$12.25 million (+356.31%). ELOX annual CFF is now -84.32% below its all-time high of $56.18 million, reached on 31 December 2018.ELOX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$3.67 M
+$2.24 M+157.00%
30 September 2023
Summary:
Eloxx Pharmaceuticals quarterly cash flow from financing activities is currently $3.67 million, with the most recent change of +$2.24 million (+157.00%) on 30 September 2023. ELOX quarterly CFF is now -93.16% below its all-time high of $53.67 million, reached on 30 June 2018.ELOX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$2.09 M
+$2.17 M+50.94%
30 September 2023
Summary:
Eloxx Pharmaceuticals TTM cash flow from financing activities is currently -$2.09 million, with the most recent change of +$2.17 million (+50.94%) on 30 September 2023. ELOX TTM CFF is now -102.97% below its all-time high of $70.28 million, reached on 31 March 2019.ELOX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ELOX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +356.3% | +9.4% | -104.2% |
| 5 y5 years | -84.3% | +3263.8% | -104.3% |
ELOX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -82.7% | +356.3% | -47.6% | +148.9% | -103.7% | +63.3% |
| 5 y | 5 years | -84.3% | +356.3% | -92.1% | +148.9% | -103.7% | +63.3% |
| alltime | all time | -84.3% | +356.3% | -93.2% | +148.9% | -103.0% | +63.3% |
Eloxx Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | $3.67 M(+157.0%) | -$2.09 M(-50.9%) |
| June 2023 | - | $1.43 M(-119.0%) | -$4.26 M(-25.1%) |
| Mar 2023 | - | -$7.50 M(-2503.8%) | -$5.69 M(-164.5%) |
| Dec 2022 | $8.81 M(-82.6%) | $312.00 K(-79.2%) | $8.81 M(+5.7%) |
| Sept 2022 | - | $1.50 M(>+9900.0%) | $8.34 M(-18.2%) |
| June 2022 | - | $0.00(-100.0%) | $10.20 M(-82.0%) |
| Mar 2022 | - | $7.00 M(-4475.0%) | $56.53 M(+11.3%) |
| Dec 2021 | $50.79 M(-1577.3%) | -$160.00 K(-104.8%) | $50.79 M(+2.2%) |
| Sept 2021 | - | $3.35 M(-92.8%) | $49.70 M(+10.2%) |
| June 2021 | - | $46.33 M(+3571.2%) | $45.09 M(-2763.6%) |
| Mar 2021 | - | $1.26 M(-200.8%) | -$1.69 M(-50.8%) |
| Dec 2020 | -$3.44 M(-107.3%) | -$1.25 M(+0.4%) | -$3.44 M(+106.2%) |
| Sept 2020 | - | -$1.25 M(+173.5%) | -$1.67 M(+211.0%) |
| June 2020 | - | -$456.00 K(-5.6%) | -$536.00 K(-101.7%) |
| Mar 2020 | - | -$483.00 K(-193.1%) | $32.22 M(-31.2%) |
| Dec 2019 | $46.80 M(-16.7%) | $519.00 K(-547.4%) | $46.80 M(-4.1%) |
| Sept 2019 | - | -$116.00 K(-100.4%) | $48.79 M(-0.3%) |
| June 2019 | - | $32.30 M(+129.1%) | $48.91 M(-30.4%) |
| Mar 2019 | - | $14.10 M(+462.2%) | $70.28 M(+25.1%) |
| Dec 2018 | $56.18 M(+48.0%) | $2.51 M(>+9900.0%) | $56.18 M(+4.7%) |
| Sept 2018 | - | $8000.00(-100.0%) | $53.68 M(-2.7%) |
| June 2018 | - | $53.67 M(>+9900.0%) | $55.17 M(+2964.9%) |
| Mar 2018 | - | $0.00(-100.0%) | $1.80 M(-30.8%) |
| Dec 2017 | $37.95 M(+3350.0%) | - | - |
| Sept 2017 | - | $1.50 M(+400.0%) | $2.60 M(+136.4%) |
| June 2017 | - | $300.00 K(-40.0%) | $1.10 M(+37.5%) |
| June 2017 | $1.10 M(-4.5%) | - | - |
| Mar 2017 | - | $500.00 K(+66.7%) | $800.00 K(+166.7%) |
| Dec 2016 | - | $300.00 K(>+9900.0%) | $300.00 K(>+9900.0%) |
| Sept 2016 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 2016 | $1.15 M(-76.1%) | $0.00(0.0%) | $1.15 M(-80.7%) |
| Mar 2016 | - | $0.00(0.0%) | $5.98 M(0.0%) |
| Dec 2015 | - | $0.00(-100.0%) | $5.98 M(0.0%) |
| Sept 2015 | - | $1.15 M(-76.1%) | $5.98 M(+23.9%) |
| June 2015 | $4.83 M(-44.7%) | $4.83 M(>+9900.0%) | $4.83 M(+6336.8%) |
| Mar 2015 | - | $0.00(0.0%) | $75.00 K(-99.1%) |
| Sept 2014 | - | $0.00(-100.0%) | $8.73 M(-0.0%) |
| June 2014 | $8.73 M(+116.5%) | $75.00 K(-95.8%) | $8.73 M(-10.5%) |
| Mar 2014 | - | $1.79 M(-73.9%) | $9.76 M(-9.7%) |
| Dec 2013 | - | $6.86 M(>+9900.0%) | $10.80 M(+174.3%) |
| Sept 2013 | - | $300.00(-100.0%) | $3.94 M(-2.3%) |
| June 2013 | $4.03 M(+24.9%) | $1.10 M(-61.2%) | $4.03 M(+37.2%) |
| Mar 2013 | - | $2.84 M(>+9900.0%) | $2.94 M(+3.2%) |
| Dec 2012 | - | $0.00(-100.0%) | $2.85 M(-0.8%) |
| Sept 2012 | - | $94.20 K(+946.7%) | $2.87 M(-11.1%) |
| June 2012 | $3.23 M | $9000.00(-99.7%) | $3.23 M(-0.4%) |
| Mar 2012 | - | $2.75 M(>+9900.0%) | $3.24 M(+63.2%) |
| Dec 2011 | - | $22.10 K(-95.1%) | $1.99 M(-6.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $451.10 K(+1941.2%) | $2.11 M(+27.1%) |
| June 2011 | $1.66 M(-86.3%) | $22.10 K(-98.5%) | $1.66 M(-86.6%) |
| Mar 2011 | - | $1.49 M(+898.1%) | $12.39 M(+13.3%) |
| Dec 2010 | - | $149.30 K(>+9900.0%) | $10.93 M(-2.9%) |
| Sept 2010 | - | $0.00(-100.0%) | $11.26 M(-7.3%) |
| June 2010 | $12.15 M(>+9900.0%) | $10.75 M(>+9900.0%) | $12.15 M(+766.6%) |
| Mar 2010 | - | $37.60 K(-92.2%) | $1.40 M(+2.8%) |
| Dec 2009 | - | $480.50 K(-45.6%) | $1.36 M(+54.4%) |
| Sept 2009 | - | $883.60 K(>+9900.0%) | $883.60 K(>+9900.0%) |
| June 2009 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2009 | - | $0.00(0.0%) | $2.70 M(+1.8%) |
| Dec 2008 | - | $0.00(0.0%) | $2.65 M(-64.7%) |
| Sept 2008 | - | $0.00(-100.0%) | $7.50 M(-13.7%) |
| June 2008 | $8.69 M(+330.3%) | $2.70 M(-5874.7%) | $8.69 M(+45.0%) |
| Mar 2008 | - | -$46.70 K(-101.0%) | $5.99 M(-0.8%) |
| Dec 2007 | - | $4.85 M(+307.3%) | $6.04 M(+88.1%) |
| Sept 2007 | - | $1.19 M(>+9900.0%) | $3.21 M(+58.9%) |
| June 2007 | $2.02 M(>+9900.0%) | $0.00(0.0%) | $2.02 M(-0.0%) |
| Mar 2007 | - | $0.00(-100.0%) | $2.02 M(-0.5%) |
| Dec 2006 | - | $2.02 M(>+9900.0%) | $2.03 M(>+9900.0%) |
| Sept 2006 | - | $100.00(0.0%) | $9800.00(+1.0%) |
| June 2006 | $9700.00(-99.7%) | $100.00(-99.0%) | $9700.00(-99.7%) |
| Mar 2006 | - | $9600.00(>+9900.0%) | $2.95 M(-0.2%) |
| Dec 2005 | - | $0.00(0.0%) | $2.95 M(-1.4%) |
| Sept 2005 | - | $0.00(-100.0%) | $2.99 M(-0.2%) |
| June 2005 | $3.00 M(-24.3%) | $2.94 M(>+9900.0%) | $3.00 M(+616.1%) |
| Mar 2005 | - | $15.00 K(-63.4%) | $418.80 K(-89.0%) |
| Dec 2004 | - | $41.00 K(+703.9%) | $3.81 M(-3.9%) |
| Sept 2004 | - | $5100.00(-98.6%) | $3.97 M(+0.1%) |
| June 2004 | $3.96 M(>+9900.0%) | $357.70 K(-89.5%) | $3.96 M(+9.9%) |
| Mar 2004 | - | $3.41 M(+1627.9%) | $3.60 M(+1630.5%) |
| Dec 2003 | - | $197.10 K(>+9900.0%) | $208.20 K(+1775.7%) |
| Sept 2003 | - | $0.00(0.0%) | $11.10 K(-50.0%) |
| June 2003 | $22.20 K(-99.6%) | $0.00(-100.0%) | $22.20 K(-98.6%) |
| Mar 2003 | - | $11.10 K(>+9900.0%) | $1.62 M(-44.2%) |
| Dec 2002 | - | $0.00(-100.0%) | $2.90 M(-49.9%) |
| Sept 2002 | - | $11.10 K(-99.3%) | $5.79 M(-6.3%) |
| June 2002 | $6.18 M(>+9900.0%) | $1.60 M(+23.5%) | $6.18 M(+34.9%) |
| Mar 2002 | - | $1.29 M(-55.2%) | $4.58 M(+37.9%) |
| Dec 2001 | - | $2.89 M(+621.6%) | $3.32 M(+663.3%) |
| Sept 2001 | - | $400.00 K(>+9900.0%) | $435.20 K(+1136.4%) |
| June 2001 | $35.20 K(-98.6%) | $0.00(-100.0%) | $35.20 K(0.0%) |
| Mar 2001 | - | $35.20 K(>+9900.0%) | $35.20 K(>+9900.0%) |
| Dec 2000 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2000 | - | $0.00 | $0.00 |
| June 2000 | $2.49 M(+24.6%) | - | - |
| June 1999 | $2.00 M(>+9900.0%) | - | - |
| June 1998 | $0.00(0.0%) | - | - |
| June 1997 | $0.00 | - | - |
FAQ
- What is Eloxx Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Eloxx Pharmaceuticals?
- What is Eloxx Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Eloxx Pharmaceuticals?
- What is Eloxx Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Eloxx Pharmaceuticals?
What is Eloxx Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ELOX is $8.81 M
What is the all time high annual CFF for Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals all-time high annual cash flow from financing activities is $56.18 M
What is Eloxx Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ELOX is $3.67 M
What is the all time high quarterly CFF for Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals all-time high quarterly cash flow from financing activities is $53.67 M
What is Eloxx Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ELOX is -$2.09 M
What is the all time high TTM CFF for Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals all-time high TTM cash flow from financing activities is $70.28 M